$8.73
-0.17[-1.91%]
At close: May 10
$8.73
0[0.00%]
After Hours: 4:00PM EDT
Actinium Pharma
(AMEX:ATNM)Latest News for Actinium Pharma Stock (AMEX:ATNM)
Actinium Pharma Stock (AMEX: ATNM)
Categories: All
Thursday, May 02, 2024
Tuesday, April 30, 2024
Monday, April 29, 2024
Monday, April 01, 2024
- HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $50 Price TargetBenzinga Newsdesk - Apr 1, 2024, 10:16AM
- Cantor Fitzgerald Reiterates Overweight on Actinium Pharma, Maintains $21 Price TargetBenzinga Newsdesk - Apr 1, 2024, 8:24AM
- Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit In High-Risk Relapsed Or Refractory Acute Myeloid Leukemia Patients With TP53 Mutations Accepted For Oral Presentation At The European Bone Marrow Transplant Annual MeetingBenzinga Newsdesk - Apr 1, 2024, 8:09AM
Tuesday, March 26, 2024
- HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $50 Price TargetBenzinga Newsdesk - Mar 26, 2024, 12:14PM
- Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell TherapyBenzinga Newsdesk - Mar 26, 2024, 7:21AM
Tuesday, March 19, 2024
- Maxim Group Maintains Buy on Actinium Pharma, Raises Price Target to $30Benzinga Newsdesk - Mar 19, 2024, 12:59PM
- Watching Actinium Pharmaceuticals; HC Wainwright: First Take Says 'Appetite Remains High For Radiopharmaceuticals; We See Actinium As Ripe For Takeout And Believes It Is Receiving M&A Interest'Benzinga Newsdesk - Mar 19, 2024, 11:24AM
- HC Wainwright & Co. Maintains Buy on Actinium Pharma, Maintains $50 Price TargetBenzinga Newsdesk - Mar 19, 2024, 11:19AM
Thursday, March 14, 2024
Monday, March 11, 2024
- HC Wainwright & Co. Maintains Buy on Actinium Pharma, Maintains $50 Price TargetBenzinga Newsdesk - Mar 11, 2024, 10:37AM
- Actinium Pharmaceuticals Has Launched A Strategic Initiative Focused On The Manufacture Of Medical Isotope Actinium-225 Leveraging Its Propriety Cyclotron-based MethodBenzinga Newsdesk - Mar 11, 2024, 7:46AM
Friday, February 09, 2024
Tuesday, December 19, 2023
Monday, December 11, 2023
- B. Riley Securities Maintains Buy on Actinium Pharma, Lowers Price Target to $16Benzinga Newsdesk - Dec 11, 2023, 11:52AM
- Actinium Announces Results From Phase 3 SIERRA Trial Of Iomab-B Presented In an Oral Presentation At 65th Annual American Society of Hematology Meeting & Exposition; Iomab-B Achieved Primary Endpoint Of Durable Complete Remission Of At Least 6 MonthsBenzinga Newsdesk - Dec 11, 2023, 8:18AM
- Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid LeukemiaBenzinga Newsdesk - Dec 11, 2023, 7:55AM
Wednesday, October 04, 2023
Tuesday, October 03, 2023
- Stocks That Hit 52-Week Lows On TuesdayBenzinga Insights - Oct 3, 2023, 2:37PM
- B. Riley Securities Reiterates Buy on Actinium Pharma, Maintains $20 Price TargetBenzinga Newsdesk - Oct 3, 2023, 1:14PM
- Watching Fusion Pharmaceuticals; Hearing Traders Circulate Note From B Riley, On Acquisition Of "PNT", Saying We Believe This Deal Validates The Value Of Late-Stage Radiopharma Assets And Shows Eli Lilly Strategic Interest In Targeted RadiotherapeuticsBenzinga Newsdesk - Oct 3, 2023, 9:35AM
Monday, October 02, 2023
Thursday, September 07, 2023
- HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $50 Price TargetBenzinga Newsdesk - Sep 7, 2023, 12:05PM
- Actinium Pharma Presents Survival Data From Extended Follow-Up From Actimab-A + CLAG-M Trial And Preclinical Data Supporting Program Expansion With FLT3 Inhibitor Combinations At SOHOHappy Mohamed - Sep 7, 2023, 8:48AM
Wednesday, September 06, 2023
Tuesday, August 15, 2023
Friday, July 14, 2023
Friday, June 23, 2023
Wednesday, June 07, 2023
Tuesday, May 16, 2023
Thursday, May 11, 2023
Wednesday, April 19, 2023
Thursday, March 09, 2023
Monday, February 27, 2023
Tuesday, February 21, 2023
- Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023Benzinga Insights - Feb 21, 2023, 10:00AM
- What's Going On With Actinium Pharmaceuticals Stock?Adam Eckert - Feb 21, 2023, 9:10AM
- Actinium Pharmaceuticals shares are trading higher after the company announced full data results from the pivotal Phase 3 SIERRA trial in patients with active, relapsed or refractory acute myeloid leukemia.Benzinga Newsdesk - Feb 21, 2023, 8:28AM
- William Blair Downgrades Actinium Pharmaceuticals to Market PerformBenzinga Newsdesk - Feb 21, 2023, 8:21AM